What does BioNTech do and what are its main business segments?

What is the market's earnings forecast for BioNTech next quarter?

What is the revenue and EPS growth rate for BioNTech year over year?

Did BioNTech beat or miss consensus estimates last quarter?

What were the key takeaways from BioNTech's earnings call?

What is BioNTech's latest dividend and current dividend yield?

What were the key takeaways from BioNTech’s earnings call?

What factors drove the changes in BioNTech's revenue and profit?

- **Pumitamig Momentum**: SCLC Phase II data (85% ORR) supports 2025 Phase III launch; €16.7B cash fuels oncology transition. 
- **Pipeline Expansion**: mRNA immunotherapies prioritize adjuvant settings; ADCs (T-PAM, BNT324) show clinical activity in SCLC, breast cancer. 
- **Financial Discipline**: 2025 revenue guidance raised to €2.6-2.8B; R&D expenses reduced by €600M via portfolio focus. 
- **Strategic Collaboration**: BMS partnership accelerates Pumitamig development; JSC ensures aligned decision-making. 
- **Growth Catalysts**: €700M BMS collaboration; 2025 loss reflects transition to commercial oncology company. 


**【CEO Summary Section】**
- BioNTech's vision is to become a global immunotherapy powerhouse, focusing on Pumitamig (PD-L1/VEGF-A bispecific) and mRNA cancer immunotherapies. 
- Q3 2025 revenue was €1.519B, up 22% YoY, driven by €700M from BMS collaboration. 
- Pumitamig Phase III trials in small cell lung cancer (SCLC) show 85% ORR at 20mg/kg, with global data consistent with China results. 
- €16.7B cash provides flexibility for oncology transition. 

**【CMO Commentary】**
- Pumitamig Wave 1 trials progressing: SCLC Phase III (ROSETTA LUNG-01) vs. atezolizumab + chemo; TNBC Phase III initiation on track. 
- mRNA immunotherapies: BNT111 in anti-PD-1 resistant melanoma shows 18% ORR, Autogene cevumeran iNeST in adjuvant settings prioritized for low tumor burden. 
- ADC pipeline: T-PAM (HER2 ADC) Phase III in China meets PFS endpoint; BNT324 (B7H3 ADC) shows 56% ORR in SCLC. 

**【CFO Financial Update】**
- 2025 revenue guidance raised to €2.6-2.8B (vs. prior €1.7-2.2B) due to BMS collaboration. 
- R&D expenses reduced by €600M to €2.0-2.2B, reflecting portfolio prioritization. 
- SG&A guidance lowered to €550-650M; CapEx €200-250M for manufacturing. 
- Net loss €29M (Q3 2025) due to contractual dispute; 2025 loss expected as transition to commercial oncology company. 

**【Q&A Highlights】**
- **Market Differentiation**: Pumitamig's VEGF/PD-L1 dual targeting addresses MSS CRC and gastric cancer unmet needs. 
- **BLA Delays**: T-PAM (BNT323) BLA pushed to 2026 due to FDA data requests; breast cancer data expected 2026. 
- **Trial Strategy**: 3-wave approach (Establish, Expand, Elevate) balances speed-to-market with combination studies. 
- **BMS Collaboration**: JSC governs decisions; BMS leads trials with optionality for BioNTech combinations. 


BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

BNTX

BNTX fundamentals

You can ask Aime